22 August 2025
22 August 2025
The deal is part of a wider $55bn investment strategy by J&J to bolster US manufacturing amid pressure from Trump.
Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy subsidiary Kite.
The agency’s approval was influenced by positive outcomes from the Phase III OASIS-HAE trial.
The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.
This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they remain agile, compliant, and strategically positioned.
The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.
By leveraging the AAV Curator platform, Amplo will progress its initiatives towards clinical assessment.
In this issue: evaluating the technical hurdles in anti-body drug conjugates (ADCs), the next wave of obesity drugs, the US-EU trade deal's affect on pharma, and more
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
